Drugs / GVAX Pancreas Vaccine (GVAX)
last change Mar 2026 re-read 2 minutes ago

GVAX Pancreas Vaccine (GVAX)

Vaccine

Developed for
malignant pancreatic neoplasm
Investigated by
Eli Lilly and Company · Merck Sharp & Dohme LLC · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03153410 Sep 2018 → Mar 2022 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GVAX Pancreas Vaccine (GVAX) ClinicalTrials.gov intervention name — accepted as the source's own label NCT03153410
Modality Vaccine “GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX)” PMID 41878443 Mar 2026